Web-economic-crisis-health-systems-and-health-web
Web-economic-crisis-health-systems-and-health-web Web-economic-crisis-health-systems-and-health-web
Country profiles of health system responses to the crisis | Greece 391 % Greece: Fig. 1 Economic and fiscal indicators 2000–2007 and 2008–2011 60 55 50 45 40 35 30 25 20 15 10 5 0 −5 −10 −15 −20 −25 −30 _ _ _ _ ● ● _ _ ● ● _ _ _ ● _ Real GDP per capita growth _ _ _ _ _ ● ● _ _ ● ● ● _ _ _ Deficit/surplus (% GDP) _ _ _ _ _ _ _ _ _ _ ● ● _ _ _ ● _ ● _ ● _ _ _ _ _ Government spending (% GDP) _ _ _ _ _ ● ● ● ● ● _ _ _ _ _ Government health spending (% total government spending) _ _ _ _ _ _ ● _ ● ● ● ● _ _ _ 10−year bond rates _ _ _ _ _ _ _ ● ● ● ● ● _ _ _ _ _ Unemployment rate Notes: Deficit/surplus: Eurostat; 10-year bond rates: European Central Bank; Other indicators: WHO Health for All. Year 2000−2007 2008 2009 2010 2011 Greece: Fig. 2 Trends in per capita spending on health, 2000–2011 2000 Public spending per capita OOP spending per capita Non−OOP private spending per capita Per capita spending $, PPP 1500 1000 500 0 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 20 Growth % 0 −20 −40 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 Public spending per capita growth OOP spending per capita growth Note: Spending calculated from WHO Health for All. Non−OOP private spending per capita growth
392 Economic crisis, health systems and health in Europe: country experience Changes to health coverage Population (entitlement) • People with a low income or who are uninsured will have free access to treatment in designated public hospitals and to generic outpatient prescription drugs from 2014 (2011). The benefits package • Reimbursement claims for hospital care must be submitted within two months (2010). • A national benefits package was established (2011). • A positive list of drugs was reintroduced (abolished in 2006), with a focus on generic drugs (2011). • Some previously covered services were excluded (e.g. polymerase chain reaction and thrombophilia tests) and cover restricted for others (childbirth, air therapy, balneotherapy, thalassaemia, logotherapy and nephropathy) mainly on the basis of their high cost (MoU 2012). • A new negative list of medicines was created based on similar lists in Spain and Italy; the list should be updated twice a year, shifting many medicines to over-the-counter status (2012). User charges • Introduction of an exemption from user charges in public facilities for people in vulnerable groups and the addition of people with diabetes and people requiring organ transplants to the list of vulnerable groups (2011). • User charges for outpatient visits in public hospitals and health centres increased from €3 to €5 (2011). • Introduction of a new co-payment of €25 per admission to a public hospital (revoked in 2014) and an additional €1 per NHS prescription in outpatient and inpatient settings from 2014 (2012). • User charges for diagnostic tests in public hospitals abolished (2012). • Co-insurance rates for drugs for specific diseases increased from 10% to 25% (rheumatoid arthritis, psoriatic arthritis, lupus, vasculitis, spondyloarthritis, scleroderma, chronic obstructive pulmonary disease, pituitary adenomas, osteoporosis, Paget's disease, Crohn's disease, cirrhosis), from 0% to 10% (Alzheimer's disease, dementia, epilepsy, angiopathy) and from 0% to 25% (pulmonary hypertension); patients requiring haemodialysis will no longer be exempt from all prescription drug user charges, just from those related to their condition (2012).
- Page 374 and 375: Country profiles of health system r
- Page 376 and 377: Country profiles of health system r
- Page 378 and 379: Country profiles of health system r
- Page 380 and 381: Country profiles of health system r
- Page 382 and 383: Bulgaria Antoniya Dimova and Mina P
- Page 384 and 385: Country profiles of health system r
- Page 386 and 387: Country profiles of health system r
- Page 388 and 389: Country profiles of health system r
- Page 390 and 391: Cyprus Elisavet Constantinou and Ma
- Page 392 and 393: Country profiles of health system r
- Page 394 and 395: Czech Republic Tomáš Roubal and J
- Page 396 and 397: Country profiles of health system r
- Page 398 and 399: Country profiles of health system r
- Page 400 and 401: Country profiles of health system r
- Page 402 and 403: Country profiles of health system r
- Page 404 and 405: Estonia Triin Habicht and Mall Lein
- Page 406 and 407: Country profiles of health system r
- Page 408 and 409: Finland Jan Klavus and Lauri Vuoren
- Page 410 and 411: Country profiles of health system r
- Page 412 and 413: France Karine Chevreul, Karen Berg
- Page 414 and 415: Country profiles of health system r
- Page 416 and 417: Country profiles of health system r
- Page 418 and 419: Country profiles of health system r
- Page 420 and 421: Germany Klaus-Dirk Henke and Wilm Q
- Page 422 and 423: Country profiles of health system r
- Page 426 and 427: Country profiles of health system r
- Page 428 and 429: Country profiles of health system r
- Page 430 and 431: Country profiles of health system r
- Page 432 and 433: Country profiles of health system r
- Page 434 and 435: Iceland Sigrún Gunnarsdóttir and
- Page 436 and 437: Country profiles of health system r
- Page 438 and 439: Ireland Anne Nolan and Steve Thomas
- Page 440 and 441: Country profiles of health system r
- Page 442 and 443: Country profiles of health system r
- Page 444 and 445: Israel Bruce Rosen and Amir Shmueli
- Page 446 and 447: Country profiles of health system r
- Page 448 and 449: Country profiles of health system r
- Page 450 and 451: Country profiles of health system r
- Page 452 and 453: Kazakhstan Ninel Kadyrova and Tata
- Page 454 and 455: Country profiles of health system r
- Page 456 and 457: Country profiles of health system r
- Page 458 and 459: Latvia Uldis Mitenbergs and Maris T
- Page 460 and 461: Country profiles of health system r
- Page 462 and 463: Country profiles of health system r
- Page 464 and 465: Country profiles of health system r
- Page 466 and 467: Country profiles of health system r
- Page 468 and 469: Country profiles of health system r
- Page 470 and 471: Malta Natasha Azzopardi Muscat Econ
- Page 472 and 473: Country profiles of health system r
Country profiles of <strong>health</strong> system responses to the <strong>crisis</strong> | Greece<br />
391<br />
%<br />
Greece: Fig. 1 Economic <strong>and</strong> fiscal indicators 2000–2007 <strong>and</strong> 2008–2011<br />
60<br />
55<br />
50<br />
45<br />
40<br />
35<br />
30<br />
25<br />
20<br />
15<br />
10<br />
5<br />
0<br />
−5<br />
−10<br />
−15<br />
−20<br />
−25<br />
−30<br />
_ _<br />
_ _<br />
● ●<br />
_ _<br />
●<br />
●<br />
_ _<br />
_<br />
●<br />
_<br />
Real GDP<br />
per capita growth<br />
_ _<br />
_ _ _<br />
● ●<br />
_ _<br />
●<br />
● ●<br />
_ _ _<br />
Deficit/surplus<br />
(% GDP)<br />
_ _ _ _ _ _ _ _<br />
_ _<br />
●<br />
●<br />
_ _<br />
_<br />
● _ ●<br />
_<br />
●<br />
_ _ _ _ _<br />
Government<br />
spending<br />
(% GDP)<br />
_ _ _ _ _<br />
● ● ● ● ●<br />
_ _ _ _ _<br />
Government<br />
<strong>health</strong> spending<br />
(% total government<br />
spending)<br />
_ _ _ _ _<br />
_ ● _ ●<br />
●<br />
●<br />
●<br />
_ _ _<br />
10−year<br />
bond rates<br />
_ _ _ _ _<br />
_ _<br />
●<br />
●<br />
●<br />
●<br />
●<br />
_ _ _ _ _<br />
Unemployment<br />
rate<br />
Notes: Deficit/surplus: Eurostat; 10-year bond rates: European Central Bank; Other indicators:<br />
WHO Health for All.<br />
Year<br />
2000−2007 2008 2009 2010 2011<br />
Greece: Fig. 2 Trends in per capita spending on <strong>health</strong>, 2000–2011<br />
2000<br />
Public spending per capita OOP spending per capita Non−OOP private spending per capita<br />
Per capita spending $, PPP<br />
1500<br />
1000<br />
500<br />
0<br />
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011<br />
20<br />
Growth %<br />
0<br />
−20<br />
−40<br />
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011<br />
Public spending<br />
per capita growth<br />
OOP spending<br />
per capita growth<br />
Note: Spending calculated from WHO Health for All.<br />
Non−OOP private spending<br />
per capita growth